AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$RVTY

Vohra Tajinder S sold $1.0M of RVTY

Vohra Tajinder S (Please See Remarks) sold 7,330 shares of REVVITY, INC. (RVTY) at $140.88 ($1.03M total) on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vohra Tajinder S
Published Sep 18, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RVTY
Bearish
medium confidence
Mentioned
$RVTY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVTYBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, offering traders a modest signal for short‑term positioning.

02

Market read

A $1M insider sale is a primary disclosure but modest in scale, yielding limited trading relevance.

03

What to watch

Potential upcoming corporate actions or earnings guidance that prompted the insider to adjust holdings.

Relevance 5/10Novelty 5/10Timing: Filed Sep 18, after market close

Background

Revvity Inc. (RVTY) is a medical technology company. Insider transactions are disclosed via Form 4 filings.

Company-level read

Ticker impact

$RVTYBearishMedium confidence
Context

Officer Vohra Tajinder S sold 7,330 shares for $1.03M via a 10b5-1 plan on Sep 16, reducing holdings to 6,635 shares.

Expected impact

Potential modest dip of 1‑2% in the near term.

Evidence & confidence

A $1M sale by an officer is material for a mid‑cap but not large enough to drive a major move; market may view it as a neutral to slightly negative signal.

Market effects

Sector

Minimal impact on the broader health‑tech sector; insider sales are common and unlikely to shift sector sentiment.

Regional

US market only; no regional ripple effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals, so the stock may remain stable.

Key entities

  • Company
    Revvity Inc.

    Issuer of the Form 4 filing.

  • Officer
    Vohra Tajinder S

    Insider who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVTY insider trading history →

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min